Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Outsourcing

Ardena acquires drug substance firm

by Rick Mullin
March 26, 2018 | A version of this story appeared in Volume 96, Issue 13

Credit: Ardena
A close-up from ChemConnection's facility in the Netherlands.

Ardena, a Belgian drug services firm focused on finished-dose products, has acquired ChemConnection, a Dutch maker of active pharmaceutical ingredients (APIs) and nanomedicines. With the acquisition, Ardena will add process and analytical development services as well as capacity to make APIs in batches of up to 30 kg. ChemConnection was formed in 2012 when Merck & Co. spun off its Organon research division. The purchase will add 60 employees, bringing Ardena’s total to 200.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.